When HIV was first identified in the early 1980s, there were few drugs to treat the virus and the opportunistic infections associated with it. Since then, a number of medications have been developed to treat both HIV/AIDS and opportunistic infections. For many people, including children, these treatments have extended and improved the quality of life. Scientists at the National Institutes of Health estimate that since 1989, anti-retroviral medications have provided HIV-positive Americans with 3 million years of extended life. But none of these drugs can cure HIV/AIDS, many have side effects that can be severe, and most are expensive. What s more, after 20 years on AIDS drugs, some people — about 40,000 in the United States alone — develop resistance to the drugs and no longer respond to treatment. The new protease inhibitor darunavir is intended to help this group of people.

.Reference resource: Click Here.

Specifications
Anit-infective drugs,Anti cancer products

Characteristics
To elevate the CD4 quantity lr lymph cells ,lower the number of virus carrier of HIV infected patients.
To suppress the virus to duplicate
To strengthen the immunity,prolong the potential period,improve patients quality of liveing and lengthen their life.
Nonpoisonous and no any side effects
Indication
SAVir can ideally be used for the following patients:
Decreased CD4 quantity of lymph cells
Ratio lf CD4/CD8 is lower than 1.5(Normal value:1.5-2.0).
Decreased leucocytes and platelets.

.Reference resource: Click Here.